Terminology and Mechanisms
此内容尚不支持你的语言。
“Fat dissolver” describes a marketed objective, not a standardized formulation or mechanism. Before interpreting a study, label, adverse event, or product claim, identify the exact finished product and the term the source actually uses.
Working vocabulary
Section titled “Working vocabulary”| Term | Useful meaning | Main limitation |
|---|---|---|
| Fat-dissolving injection | Common market and public-facing term | Can make unlike products sound interchangeable |
| Injectable fat reduction | Neutral category term used in this index | Still requires product and anatomical specificity |
| Injection lipolysis | Procedure-level term for localized injections intended to reduce adipose tissue | Does not identify the injected formulation |
| Deoxycholic acid (DCA) | Active substance named in approved products such as Kybella | Approval does not transfer to another DCA-containing product |
| Sodium deoxycholate | A salt form declared in several marketed mixtures | Concentration and formulation may be absent or inconsistently documented |
| Phosphatidylcholine (PPC) | Phospholipid included in many mixed formulations | Its presence does not establish the product’s principal cytolytic component or clinical performance |
| PCDC or PC/DC | Shorthand for phosphatidylcholine plus deoxycholate mixtures | Ratios, excipients, preparation, and source can vary |
| Lipodissolve | A name used for injection-lipolysis mixtures and treatment practices | It is not one globally standardized finished product |
Deoxycholic acid is cytolytic
Section titled “Deoxycholic acid is cytolytic”The US Kybella label describes deoxycholic acid as a cytolytic drug that physically disrupts the cell membrane when injected into tissue. The resulting destruction of adipocytes produces a tissue response that includes macrophage recruitment and cellular-debris clearance (FDA prescribing information 🔗).
This is more precise than saying the product simply “melts fat.” The mechanism also explains why exposure outside the intended subcutaneous fat can injure other tissue. The label’s mechanism and safety data belong to Kybella’s tested formulation and approved context; they do not validate every solution containing deoxycholate.
Acid, salt, and finished product
Section titled “Acid, salt, and finished product”Product materials may use deoxycholic acid, deoxycholate, and sodium deoxycholate with inconsistent precision. For an index entry, record:
- the wording on the regulator-hosted label or manufacturer document
- the stated amount and unit
- whether the value refers to the active moiety, a salt, or a total mixture
- the excipients and presentation, when disclosed
- the market and document version
A familiar molecule does not make two products equivalent. Sterility assurance, raw-material control, concentration, pH, osmolality, excipients, vial size, labeling, and clinical evidence belong to the finished product.
PPC and deoxycholate mixtures
Section titled “PPC and deoxycholate mixtures”PPC/deoxycholate products are frequently discussed as one family, but they may differ in:
- PPC and deoxycholate amounts
- additional carnitine, peptides, vitamins, plant extracts, or other ingredients
- preservative system
- vial size and number of vials
- intended facial or body positioning
- whether the supplier identifies the item as a medicine, device, cosmetic, professional solution, or another category
- available clinical and regulatory documentation
Do not infer the composition of Lipo Lab, Dr. Lipo+, or another product from the shorthand PCDC.
Lipodissolve is not one standardized product
Section titled “Lipodissolve is not one standardized product”Lipodissolve has been used for clinic-compounded or otherwise supplied injection-lipolysis mixtures, often associated with PPC and deoxycholate. Because the term can refer to different recipes and sources, it should be indexed as a procedure and formulation concept rather than as a single brand with one composition.
The FDA includes Lipodissolve among fat-dissolving injections that are not FDA approved and warns of reports including scarring, infection, skin deformity, cysts, and painful deep nodules after unapproved products (FDA safety communication 🔗). That warning should not be rewritten as if every historical publication used one identical Lipodissolve preparation.
A practical interpretation sequence
Section titled “A practical interpretation sequence”When a source reports a result or complication, ask:
- Was the exact brand or compounded preparation identified?
- Were all active and inactive ingredients reported?
- Was the concentration stated in comparable units?
- Was the product authorized in that jurisdiction for that anatomical area?
- Was the evidence generated with the same finished formulation now being discussed?
If those questions cannot be answered, report the evidence as mixture-level or procedure-level rather than transferring it to a named product.
Nearby reference pages
Section titled “Nearby reference pages”- Product and regulatory classification separates medicines, cosmetics, device claims, and unapproved products.
- DCA drugs vs PPC/deoxycholate mixtures provides a compact comparison.
- Safety and treatment boundaries connects cytolysis with anatomy, sourcing, and follow-up.